Leukemia clinical trials in Idaho

11 actively recruiting leukemia trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed 2026-10-19

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT03150693

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Walter Knox Memorial Hospital — Emmett, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT07321652

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Idaho Urologic Institute-Meridian — Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group

NCT ID: NCT03959085

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group

NCT ID: NCT04293562

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06317649

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554406

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554393

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC

NCT ID: NCT04726241

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06124157

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06317662

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06917911

Sites in Idaho:

Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19